[Transfer] The National Medical Insurance Bureau named two pharmaceutical companies

[Transfer] The National Medical Insurance Bureau named two pharmaceutical companies

Source: Sai Bailan/Mu Zhi

01

Two pharmaceutical companies are "serious" and dishonesty

Today, the National Medical Insurance Bureau released the "Special Serious" and "serious" dishonesty assessment results (No. 3). The medical price and bidding procurement guidance center summarized the situation of various provinces from April 1, 2022 to June 30, 2022 as "particularly serious" and "serious" medical enterprises that were broken.

1. Yunnan ** Pharmaceutical Co., Ltd.

According to the Deqin County People's Court, Yunnan ** Pharmaceutical Co., Ltd. gives a rebate or improper benefit to the relevant personnel of the Diqing Shangri -La People's Hospital to obtain additional transaction opportunities, competitive advantages and sales quantities, which is equivalent to RMB More than 600,000 yuan. The effective time of the dishonesty is February 24, 2022. The provincial -level pharmaceutical centralized procurement institutions in Yunnan have evaluated the company's "serious" dishonesty in accordance with the price recruitment credit evaluation system.

2. Ningxia ** Pharmaceutical Co., Ltd.

According to the judgment of the Yinchuan Intermediate People's Court of Ningxia Hui Autonomous Region, Ningxia ** Pharmaceutical Co., Ltd. gives a rebate or improper benefit to the relevant personnel of Guyuan People's Hospital to obtain additional transaction opportunities, competition advantages and sales quantities to the drugs they operate. It's equivalent to more than 1.14 million yuan. The starting time of the timeliness of the dishonesty behavior is March 31, 2022, the centralized procurement agency of Ningxia Hui Autonomous Region, in accordance with the price recruitment credit evaluation system, evaluates the company's "serious" dishonesty.

Recently, the official website of the State Medical Insurance Bureau regularly announced the "serious" and "particularly serious" companies that broke their trust in the column of "Credit Evaluation of Price Recruitment" to increase industry warning.

In June of this year, the National Medical Insurance Bureau announced the results of the second price recruitment of credit evaluations of "serious" and "particularly serious" dishonesty evaluation results. The six pharmaceutical companies entered the list, which was the same as the two latest announcements. Personnel gives a rebate or improper interest.

02

What are the punishment for pharmaceutical companies?

Recently, it has entered a densely report period for dishonesty pharmaceutical companies. From the notification issued by the National Medical Insurance Bureau, Sichuan, Henan, Ningxia, etc., the renewal of pharmaceutical deductions is the highest -income pharmaceutical company's dishonesty behavior.

In June of this year, the Gansu Provincial Medical Insurance Bureau issued the "Notice on Publicizing the results of the results of the dishonesty in the selection of companies in Gansu Province's procurement drugs", and publicized 70 Chinese -elected enterprises that did not fulfill their commitment matters as required.

On July 1, the Jiangsu Provincial Medical Insurance Bureau announced the "Notice of the Jiangsu Provincial Public Resources Trading Center on the results of the provincial pharmaceutical price and recruitment of dishonesty level evaluation", and announced that it would be rated a medical device company with commercial bribery as a serious dishonesty.

On July 4, the centralized procurement center of Hebei Medical Drug Instrument issued the "Notice on the announcement of the results of Hebei Province's pharmaceutical prices and recruitment credit assessment results", which announced the evaluation of Hebei Province from July 1, 2021 to June 30, 2022 and June 30, 2022. The results of the medical price and recruitment of credit assessment were informed. After sorting out, there are 43 companies announced this time, all of which are "generally dishonest".

According to the "Guiding Opinions on Establishing a Medical Price and Recruitment of Credit Evaluation System" (hereinafter referred to as the "Opinions") issued by the State Medical Insurance Bureau, the nature, plot, timeliness, and influence of comprehensive dishonesty behavior, pharmaceutical companies in the local tender procurement market The assessment of the dishonesty is general, medium, severe, and particularly serious, and according to the credit rating of pharmaceutical companies, we take written reminders, restrictions, or suspension of related drugs or medical consumables.

When interpreting the "Opinions", the National Medical Insurance Bureau emphasized that enterprises should pay enough attention to the consequences of "general" or "medium". This punishment is continuous and accumulated. If it is not corrected in time, the negative effects of the newly formed will cause the rating results to accumulate or even upgrade.

For example, the "general" dishonesty will progress into "medium" and dishonesty, and 3 "medium" dishonesty will progress into "serious" dishonesty. Enterprise applications are good for credit restoration rules. For example, for "rebate" behavior, the repair measures available for enterprises have both returned improper income and price reduction to eliminate price virtual high space.

In the price recruitment credit evaluation, it is rated as "serious" and "particularly serious" enterprises, and it is facing the restrictions or suspension of drugs or medical consumables involved in the case, bidding or distribution qualifications. Accept such a penalty.

03

Multiple measures to combine efforts, standardize the pharmaceutical market

Drug rebates and monopoly and sales have caused the high price of drugs and the burden of patients with the medicine. In the deepening of policies such as the procurement of volume in recent years, related issues have been relieved, but the gray areas still exist.

On the one hand, the purchase of volume involves only some clinical drugs; on the other hand, in the early days of policy implementation, some companies have malicious disruption of the order of collecting order.

Based on this situation, for the pharmaceutical rebate behavior, the pharmaceutical price and credit evaluation system can conduct market restrictions on related enterprises through criminal accountability and administrative penalties to form a "combination boxing" supervision to increase the pressure on business bribery in business bribery.

Under the medical recruitment credit evaluation system, pharmaceutical companies shall submit a written commitment to the relevant recruitment agencies in the name of independent legal persons. According to regulations, whether it is a self -employed team or an external agent, as long as there is a problem in the promotion process, it can be collected on a pharmaceutical company that submits credit commitments.

In addition, in recent years, with the normalization of band purchases, there are more and more varieties involved, and the market influence has gradually appeared. According to the "Fourteenth Five -Year Plan for the National Medical Security Plan", to the end of the "Fourteenth Five -Year Plan", more than 500 national and provincial drug -level drug -level procurement varieties of provinces (autonomous regions, municipalities) are procurement. In other words, Jicai has become an indispensable way for enterprises to develop, and the increase in the importance of enterprises' attention to the purchase of volume has also increased the influence of the medical recruitment credit evaluation system.

The seventh batch of national ministry stipulates that it is judged as "serious" or "particularly serious" level of dishonesty or the selection of varieties in the two years of selection. In the confirmation, none of them have the qualifications to choose the area for the first time, that is, a relatively missing supply area is relatively missing, and then greatly deepen the application strength and intensity of the recruitment credit system.

However, pharmaceutical companies also need to understand that the fundamental purpose of credit evaluation is not to be punished for punishment, but to regulate the price and recruitment behavior in the field of medical circulation to protect the vital interests of patients.

Because of this, the "Guidance Opinions" also established a credit repair mechanism of pharmaceutical enterprises, encouraging enterprises to take practical measures to actively repair credit, including termination of related dishonesty, returning or unreasonable benefits of public welfare donations, and eliminating the price of drugs or medical consumables involved in the case. The virtual high space and so on.

However, it should be noted that in response to the severe dishonesty of illegal bidding and violations of commitments, the Medical Insurance Bureau does not accept proactive repair, which reflects the national level of focus on concentrated procurement and the concerns of meeting clinical needs. This is also the last "red line".

It can be seen from the recent various signals that in the future, the rectification of medicine rebates may become more and more stringent.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -